scholarly journals Center for International Blood and Marrow Transplant Research Chronic Graft-versus-Host Disease Risk Score Predicts Mortality in an Independent Validation Cohort

2015 ◽  
Vol 21 (4) ◽  
pp. 640-645 ◽  
Author(s):  
Mukta Arora ◽  
Michael T. Hemmer ◽  
Kwang Woo Ahn ◽  
John P. Klein ◽  
Corey S. Cutler ◽  
...  
Keyword(s):  
Risk Score ◽  
Graft Versus Host Disease ◽  
Validation Cohort ◽  
Disease Risk ◽  
Marrow Transplant ◽  
Host Disease ◽  
Graft Versus Host ◽  
Independent Validation ◽  
Blood And Marrow Transplant ◽  
Disease Risk Score

scholarly journals Amphiregulin Modifies the Minnesota Acute Graft-Versus-Host Disease Risk Score: Results from BMT CTN Acute Gvhd Therapy Trials

2018 ◽  
Vol 24 (3) ◽  
pp. S177-S178
Author(s):  
Shernan G. Holtan ◽  
Todd E. Defor ◽  
Alan Howard ◽  
Joseph A. Pidala ◽  
John E. Levine ◽  
...  
Keyword(s):  
Risk Score ◽  
Graft Versus Host Disease ◽  
Acute Gvhd ◽  
Disease Risk ◽  
Host Disease ◽  
Graft Versus Host ◽  
Disease Risk Score ◽  
Acute Graft

scholarly journals Validation of Minnesota acute graft-versus-host disease Risk Score

Haematologica ◽  
2019 ◽  
Vol 105 (2) ◽  
pp. 519-524 ◽  
Author(s):  
Margaret L. MacMillan ◽  
Todd E. DeFor ◽  
Shernan G. Holtan ◽  
Armin Rashidi ◽  
Bruce R. Blazar ◽  
...  
Keyword(s):  
Risk Score ◽  
Graft Versus Host Disease ◽  
Disease Risk ◽  
Host Disease ◽  
Graft Versus Host ◽  
Disease Risk Score ◽  
Acute Graft

scholarly journals Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802

2018 ◽  
Vol 2 (15) ◽  
pp. 1882-1888 ◽  
Author(s):  
Shernan G. Holtan ◽  
Todd E. DeFor ◽  
Angela Panoskaltsis-Mortari ◽  
Nandita Khera ◽  
John E. Levine ◽  
...  
Keyword(s):  
Risk Score ◽  
Graft Versus Host Disease ◽  
Disease Risk ◽  
Host Disease ◽  
Graft Versus Host ◽  
Steroid Response ◽  
Disease Risk Score ◽  
Key Points ◽  
Acute Graft

Key Points High-circulating AREG (≥33 pg/mL) reclassifies additional patients into HR categories and further refines the Minnesota aGVHD risk score. Patients with aGVHD and AREG ≥33 pg/mL have lower rates of steroid response, higher NRM, and poorer OS.

scholarly journals A New Standard in Graft-versus-Host Disease Prophylaxis? An Introduction to Blood and Marrow Transplant Clinical Trials Network 1703

2020 ◽  
Vol 26 (12) ◽  
pp. e305-e308
Author(s):  
Zachariah DeFilipp ◽  
Linda J. Burns ◽  
Samantha M. Jaglowski ◽  
Aaron L. Leppin ◽  
Steven Pavletic ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Graft Versus Host Disease ◽  
Marrow Transplant ◽  
Host Disease ◽  
Graft Versus Host ◽  
Blood And Marrow Transplant

scholarly journals Tools for the Precision Medicine Era: How to Develop Highly Personalized Treatment Recommendations From Cohort and Registry Data Using Q-Learning

2017 ◽  
Vol 186 (2) ◽  
pp. 160-172 ◽  
Author(s):  
Elizabeth F Krakow ◽  
Michael Hemmer ◽  
Tao Wang ◽  
Brent Logan ◽  
Mukta Arora ◽  
...  
Keyword(s):  
Graft Versus Host Disease ◽  
Controlled Trial ◽  
Treatment Strategies ◽  
Marrow Transplant ◽  
Host Disease ◽  
Q Learning ◽  
Graft Versus Host ◽  
Adaptive Treatment ◽  
Blood And Marrow Transplant ◽  
Multiple Assignment

Abstract Q-learning is a method of reinforcement learning that employs backwards stagewise estimation to identify sequences of actions that maximize some long-term reward. The method can be applied to sequential multiple-assignment randomized trials to develop personalized adaptive treatment strategies (ATSs)—longitudinal practice guidelines highly tailored to time-varying attributes of individual patients. Sometimes, the basis for choosing which ATSs to include in a sequential multiple-assignment randomized trial (or randomized controlled trial) may be inadequate. Nonrandomized data sources may inform the initial design of ATSs, which could later be prospectively validated. In this paper, we illustrate challenges involved in using nonrandomized data for this purpose with a case study from the Center for International Blood and Marrow Transplant Research registry (1995–2007) aimed at 1) determining whether the sequence of therapeutic classes used in graft-versus-host disease prophylaxis and in refractory graft-versus-host disease is associated with improved survival and 2) identifying donor and patient factors with which to guide individualized immunosuppressant selections over time. We discuss how to communicate the potential benefit derived from following an ATS at the population and subgroup levels and how to evaluate its robustness to modeling assumptions. This worked example may serve as a model for developing ATSs from registries and cohorts in oncology and other fields requiring sequential treatment decisions.

Evaluation of pentostatin in corticosteroid-refractory chronic graft-versus-host disease in children: a Pediatric Blood and Marrow Transplant Consortium study

Blood ◽  
2009 ◽  
Vol 114 (20) ◽  
pp. 4354-4360 ◽  
Author(s):  
David A. Jacobsohn ◽  
Andrew L. Gilman ◽  
Alfred Rademaker ◽  
Brittan Browning ◽  
Michael Grimley ◽  
...  
Keyword(s):  
Confidence Interval ◽  
Graft Versus Host Disease ◽  
Chronic Gvhd ◽  
Joint Damage ◽  
Normal Growth ◽  
Marrow Transplant ◽  
Host Disease ◽  
Graft Versus Host ◽  
Blood And Marrow Transplant ◽  
Steroid Refractory

Abstract There is no standard therapy for steroid-refractory chronic graft-versus-host disease (GVHD). This problem is particularly daunting in children with chronic GVHD, whereby the effects of the disease and its treatment may impair normal growth and development. Children are also particularly vulnerable to failure and/or toxicity of therapy; for example, joint contractures or joint damage may result in life-long disability. The Pediatric Blood and Marrow Transplant Consortium performed a phase 2 trial of pentostatin for steroid-refractory chronic GVHD in 51 children (median age, 9.8 years) from 24 institutions. Overall response was 53% (95% confidence interval, 40%-64%), with a response of 59% (95% confidence interval, 42%-75%) in sclerosis. Thirteen subjects (25%) had toxicity requiring them to stop pentostatin. The drug had a significant steroid-sparing effect in those that responded. A trend was also observed toward increased survival at 3 years in responders versus nonresponders (69% vs 50%; P = .06). The intravenous administration of the drug ensures compliance in a patient group in which oral therapy is difficult to monitor. Pentostatin has activity in refractory chronic GVHD in children, and future studies, including treatment of children newly diagnosed with high-risk chronic GVHD, are warranted. The trial was registered at www.Clinicaltrials.gov as #NCT00144430.

Sign in / Sign up

Export Citation Format

Share Document